All In Biotech

Drug Trial Radar · NCT01907867

Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin

An Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin After Single and Multiple Doses Administered Orally in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Feb 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Jan 2012

Primary completion

Feb 2012

Study completion Feb 2012

Sponsor

Lead sponsor
MerLion Pharmaceuticals GmbHIndustry
Sponsor type
Industry
First posted
Jul 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study investigates the safety, tolerability, and PK profile of finafloxacin as a novel fluoroquinolone and a potential therapeutic agent for lower respiratory infections such as bacterial pneumonia. A comparison of the PK profile of finafloxacin in plasma and lung ELF using different bronchoscopic ELF sampling techniques (BMS and BAL) is conducted.

Conditions

  • Safety and Tolerability

Interventions

  • Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 daysDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of orally administered finafloxacin in healthy subjects.Time frame: Day 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pulmonary Associates, PA

    Phoenix, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.